35 articles · Page 3
Notion lost access to Anthropic's API and millions of users hit a wall. Meanwhile, OpenAI is rebuilding ChatGPT into an AI super app targeting enterprise revenue above 50% of total income. The free tier
Anthropic just expanded Project Glasswing to 150 new organizations across 15+ countries, giving NATO, Samsung, and ENISA access to Claude Mythos. The AI has already flagged over 23,000 vulnerabilities inside partner codebases. Here's what
Anthropic just raised $65 billion and is nearing a $1 trillion valuation before it goes public. Most people are reading this as a tech story. It's actually a wealth transfer story, and the window
Anthropic signed a lease with SpaceX and nobody agrees on how long it runs. The debate isn't just about square footage. It's a signal about Anthropic's confidence, its next fundraise, and where the real
Andrej Karpathy just joined Anthropic's pretraining team, and the enterprise AI market will never be the same. With $450 billion in financial services AI spend up for grabs by 2027, this hire reshuffles every
SandboxAQ just brought its molecular simulation models into Claude's AI platform. Biotech founders can now run drug discovery experiments through plain language queries without building expensive computational infrastructure. The incumbents won't like what comes
SandboxAQ just plugged its molecular simulation models into Claude, making drug discovery tools accessible without a team of specialists. The average drug costs $2.6 billion to develop. That access barrier just dropped for smaller
SandboxAQ just made its drug discovery models accessible inside Claude, no specialized computing background required. The average drug costs $2.6 billion to develop. That math is about to change for anyone paying attention. Here's
SandboxAQ has brought its Large Quantitative Models for molecular simulation into the Claude interface. Drug discovery that once required supercomputers and specialized teams now runs through a browser tab. Here's what that actually means
SandboxAQ connected its drug discovery AI to Claude, putting simulation tools that once cost tens of thousands of dollars into any researcher's browser. The science story is interesting. The money story is bigger. Here's